Adcetris Dosage

Generic name: Brentuximab Vedotin 50mg in 10.5mL
Dosage form: injection, powder, lyophilized, for solution
Drug class: CD30 monoclonal antibodies

Medically reviewed by Drugs.com. Last updated on Feb 19, 2025.

Recommended Dosage

The recommended ADCETRIS dosage is provided in Table 1. Administer ADCETRIS as a 30-minute intravenous infusion.

For recommended dosage for patients with renal or hepatic impairment, see Dosage and Administration (2.2 and 2.3).

For dosing instructions of combination agents administered with ADCETRIS, see Clinical Studies (14.1, 14.2, and 14.5) and the manufacturer’s prescribing information.

Table 1: Recommended ADCETRIS Dosage
* The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg. † Starting with cycle 2, rituximab intravenous treatment could be substituted with rituximab and hyaluronidase human via subcutaneous injection every 3 weeks.
Indication	Recommended Dose*	Frequency and Duration
Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma	1.2 mg/kg up to a maximum of 120 mg in combination with chemotherapy	Administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity
Pediatric patients with previously untreated high risk classical Hodgkin lymphoma	1.8 mg/kg up to a maximum of 180 mg in combination with chemotherapy	Administer every 3 weeks with each cycle of chemotherapy for a maximum of 5 doses
Adult patients with classical Hodgkin lymphoma consolidation	1.8 mg/kg up to a maximum of 180 mg	Initiate ADCETRIS treatment within 4‑6 weeks post-auto-HSCT or upon recovery from auto-HSCT Administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
Adult patients with relapsed classical Hodgkin lymphoma	1.8 mg/kg up to a maximum of 180 mg	Administer every 3 weeks until disease progression or unacceptable toxicity
Adult patients with previously untreated systemic ALCL or other CD30-expressing peripheral T-cell lymphomas	1.8 mg/kg up to a maximum of 180 mg in combination with chemotherapy	Administer every 3 weeks with each cycle of chemotherapy for 6 to 8 doses
Adult patients with relapsed Systemic ALCL	1.8 mg/kg up to a maximum of 180 mg	Administer every 3 weeks until disease progression or unacceptable toxicity
Adult patients with relapsed primary cutaneous ALCL or CD30-expressing mycosis fungoides	1.8 mg/kg up to a maximum of 180 mg	Administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity
Adult patients with relapsed or refractory LBCL	1.2 mg/kg up to a maximum of 120 mg in combination with lenalidomide and rituximab†	Administer every 3 weeks until disease progression, or unacceptable toxicity

Recommended Dosage in Patients with Renal Impairment

No dosage adjustment is required for mild renal impairment (CrCL greater than 50‑80 mL/min) and moderate renal impairment (CrCL 30-50 mL/min).

Avoid use in patients with severe (CrCL less than 30 mL/min) renal impairment.

Recommended Dosage in Patients with Hepatic Impairment

Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma

Reduce the dosage of ADCETRIS to 0.9 mg/kg up to a maximum of 90 mg every 2 weeks for patients with mild hepatic impairment (Child-Pugh A).

Avoid use in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment.

Adult patients with relapsed or refractory LBCL

Reduce the dosage of ADCETRIS to 0.9 mg/kg up to a maximum of 90 mg every 3 weeks for patients with mild hepatic impairment (total bilirubin ≤ upper limit of normal [ULN] and aspartate transaminase [AST] > ULN, or total bilirubin >1 to 1.5 × ULN and any AST).

Avoid use in patients with moderate and severe hepatic impairment (total bilirubin >1.5 × ULN).

Hepatic impairment is defined per the National Cancer Institute Organ Dysfunction Working Group.

All other indications

Reduce the dosage of ADCETRIS to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks for patients with mild hepatic impairment (Child-Pugh A).

Avoid use in patients with moderate (Child-Pugh B) and severe (Child-Pugh C) hepatic impairment.

Recommended Prophylactic Medications

In adult patients with previously untreated Stage III or IV cHL who are treated with ADCETRIS + doxorubicin, vinblastine, and dacarbazine (AVD), administer G‑CSF beginning with Cycle 1.

In pediatric patients with previously untreated high risk cHL who are treated with ADCETRIS + doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide (AVEPC), administer G-CSF beginning with Cycle 1.

In adult patients with previously untreated PTCL who are treated with ADCETRIS + cyclophosphamide, doxorubicin, and prednisone (CHP), administer G-CSF beginning with Cycle 1.

In adult patients with relapsed or refractory LBCL who are treated with ADCETRIS + lenalidomide + rituximab, administer G-CSF beginning with Cycle 1.

Dosage Modifications for Adverse Reactions

Table 2: Dosage Modifications for Peripheral Neuropathy or Neutropenia in Adult Patients
* The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg. † Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) Version 5.
Recommended ADCETRIS Dosage from Table 1*	Monotherapy or Combination Therapy	Severity†	Dosage Modification
Peripheral Neuropathy
1.2 mg/kg up to a maximum of 120 mg every 2 weeks	In combination with chemotherapy	Grade 2	Reduce dose to 0.9 mg/kg up to a maximum of 90 mg every 2 weeks.
		Grade 3	Hold ADCETRIS dosing until improvement to Grade 2 or lower. Restart at 0.9 mg/kg up to a maximum of 90 mg every 2 weeks. Consider modifying the dose of other neurotoxic chemotherapy agents.
		Grade 4	Discontinue dosing.
1.2 mg/kg up to a maximum of 120 mg every 3 weeks	In combination with lenalidomide and rituximab	Grade 2	Sensory neuropathy: If resolves to Grade 1 or lower before the next scheduled dose, resume at the same dose level. If Grade 2 persists at the next scheduled dose, reduce one dose level. Motor neuropathy: Reduce dosage to 0.9 mg/kg up to a maximum of 90 mg every 3 weeks.
		Grade 3	Sensory neuropathy: Hold ADCETRIS dosing until improvement to Grade 2 or lower, then restart treatment at a reduced dosage of 0.9 mg/kg up to a maximum of 90 mg every 3 weeks. Motor neuropathy: Discontinue dosing.
		Grade 4	Discontinue dosing.
1.8 mg/kg up to a maximum of 180 mg every 3 weeks	As monotherapy	New or worsening Grade 2 or 3	Hold dosing until improvement to baseline or Grade 1. Restart at 1.2 mg/kg up to a maximum of 120 mg every 3 weeks.
	As monotherapy	Grade 4	Discontinue dosing.
	In combination with chemotherapy	Grade 2	Sensory neuropathy: Continue treatment at same dose. Motor neuropathy: Reduce dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks.
		Grade 3	Sensory neuropathy: Reduce dose to 1.2 mg/kg, up to a maximum of 120 mg every 3 weeks. Motor neuropathy: Discontinue dosing.
		Grade 4	Discontinue dosing.
Neutropenia
1.2 mg/kg up to a maximum of 120 mg every 2 weeks	In combination with chemotherapy	Grade 3 or 4	Administer G‑CSF prophylaxis for subsequent cycles for patients not receiving primary G‑CSF prophylaxis.
1.2 mg/kg up to a maximum of 120 mg every 3 weeks	In combination with lenalidomide and rituximab	Grade 3 or 4	Hold dosing until improvement to baseline or Grade 2 or lower. Reduce/discontinue lenalidomide dose per prescribing information. Administer G-CSF prophylaxis for subsequent cycles for patients not receiving primary G-CSF prophylaxis.
1.8 mg/kg up to a maximum of 180 mg every 3 weeks	In combination with chemotherapy	Grade 3 or 4	Administer G-CSF prophylaxis in subsequent cycles for patients not receiving primary G-CSF prophylaxis.
1.8 mg/kg up to a maximum of 180 mg every 3 weeks	As monotherapy	Grade 3 or 4	Hold dosing until improvement to baseline or Grade 2 or lower. Consider G-CSF prophylaxis for subsequent cycles.
1.8 mg/kg up to a maximum of 180 mg every 3 weeks	As monotherapy	Recurrent Grade 4 despite G‑CSF prophylaxis	Consider discontinuation or dose reduction to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks.

Table 3: Dosage Modifications for Peripheral Neuropathy or Neutropenia in Pediatric Patients
* The dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg. † Peripheral neuropathy was assessed using the Balis scale.
Recommended ADCETRIS Dosage from Table 1*	Severity	Dosage Modification
Peripheral Neuropathy†
1.8 mg/kg up to a maximum of 180 mg every 3 weeks	Grade 2†	Reduce dose of vincristine per prescribing information. Continue dosing with ADCETRIS. If neuropathy improves to Grade ≤1 by day 8 of next cycle, then resume vincristine at full dose.
	Grade 3†	Discontinue vincristine. First Occurrence: Hold ADCETRIS dosing until improvement to ≤ Grade 2 then restart at 1.2 mg/kg up to a maximum of 120 mg. Second Occurrence: Hold until improvement to ≤ Grade 2 then restart at 0.8 mg/kg up to a maximum of 80 mg. Third Occurrence: Discontinue ADCETRIS.
	Grade 4†	Discontinue ADCETRIS and vincristine.
Neutropenia
1.8 mg/kg up to a maximum of 180 mg every 3 weeks	Grade 3 or 4	Reduce dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks in patients who are unable to start a cycle >5 weeks after the start of the previous cycle (>2-week delay) due to neutropenia.

Instructions for Preparation and Administration

Administration

•: Administer ADCETRIS as an intravenous infusion only.
•: Do not mix ADCETRIS with, or administer as an infusion with, other medicinal products.

Reconstitution

•: Follow procedures for proper handling and disposal of hazardous drugs1.
•: Use appropriate aseptic technique for reconstitution and preparation of dosing solutions.
•: Determine the number of 50 mg vials needed based on the patient’s weight and the prescribed dose.
•: Reconstitute each 50 mg vial of ADCETRIS with 10.5 mL of Sterile Water for Injection to yield a single-dose solution containing 5 mg/mL brentuximab vedotin.
•: Direct the stream toward the wall of vial and not directly at the cake or powder.
•: Gently swirl the vial to aid dissolution. DO NOT SHAKE.
•: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted solution should be clear to slightly opalescent, colorless, and free of visible particulates.
•: Following reconstitution, dilute immediately into an infusion bag. If not diluted immediately, store the solution refrigerated at 2°C to 8°C (36°F to 46°F) and use within 24 hours of reconstitution. DO NOT FREEZE.
•: Discard any unused portion left in the vial.

Dilution

•: Calculate the required volume of 5 mg/mL reconstituted ADCETRIS solution needed.
•: Withdraw this amount from the vial and immediately add it to an infusion bag containing 0.9% Sodium Chloride Injection, USP, 5% Dextrose Injection or Lactated Ringer's Injection to achieve a final concentration of 0.4 mg/mL to 1.8 mg/mL brentuximab vedotin.
•: Gently invert the bag to mix the solution.
•: Following dilution, infuse the ADCETRIS solution immediately. If not used immediately, store the solution refrigerated at 2°C to 8°C (36°F to 46°F) and use within 24 hours of reconstitution. DO NOT FREEZE.